Abstract

Transforming growth factor-β (TGF-β) signaling pathways are well-recognized for their role in proliferation and epithelial–mesenchymal transition (EMT) of cancer cells, but much less is understood about their contribution to interactions with other signaling events. Recent studies have indicated that crosstalk between TGF-β and Ras signaling makes a contribution to TGF-β-mediated EMT. Here, we demonstrate that Jumonji domain containing-3 (JMJD3 also called KDM6B) promotes TGF-β-mediated Smad activation and EMT in Ras-activated lung cancer cells. JMJD3 in lung cancer patients was significantly increased and JMJD3 expression in lung tumor tissues was correlated with expression of K-Ras or H-Ras in particular, and its expression was regulated by Ras activity in lung cancer cells. JMJD3 promotes TGF-β-induced Smad activation and EMT in Ras-activated lung cancer cells through the induction of syntenin, a protein that regulates TGF-β receptor activation upon ligand binding. Tissue array and ChIP analysis revealed that JMJD3 epigenetically induces syntenin expression by directly regulating H3K27 methylation levels. Mechanical exploration identified a physical and functional association of JMJD3 with syntenin presiding over the TGF-β in Ras-activated lung cancer cells. Taken together, these findings provide new insight into the mechanisms by which JMJD3 promotes syntenin expression resulting in oncogenic Ras cooperation with TGF-β to promote EMT.

Highlights

  • Transforming growth factor-β (TGF-β) is one of the main growth factors involved in driving epithelial–mesenchymal transition (EMT)

  • In order to determine the role of JMJD3 in human lung cancer, we first explored human lung cancer patients within the Gene Expression Omnibus database (GEO) database and examined several human lung cancer cell lines to determine whether abnormal JMJD3 expression existed

  • To evaluate whether differential expression of JMJD3 plays a role in human lung cancer progression, we explored the association between JMJD3 mRNA levels and overall survival in a cohort of human lung cancer patients from Kaplan–Meier plotter (KM Plotter)

Read more

Summary

Introduction

Transforming growth factor-β (TGF-β) is one of the main growth factors involved in driving EMT. The Jumonji domain containing-3 (JMJD3), known as lysine (K)-specific demethylase 6B (KDM6B), is a member of the Fe(II)- and α-ketoglutarate-dependent demethylases that activate gene expression by removing H3K27me[3] marks on gene promoters[22,23,24]. JMJD3 has been shown to be involved in tumor progression via regulation of cell proliferation, migration, and senescence[26,27,28,29], and its expression is significantly increased in human prostate cancer cells, gliomas, and renal cancer cells compared to adjacent normal tissue[30,31]. High level of JMJD3 induces the expression of mesenchymal genes such as Snail and Slug, which promote TGF-β-induced EMT and tumor metastasis[32,33,34]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call